Pfizer is one of the world’s premier innovative biopharmaceutical companies, discovering, developing and providing over 100 different medicines, vaccines and consumer healthcare products that help save and transform the lives of millions of people in the UK and around the world every year.
For more than 25 years, Pfizer Endocrine Care has been committed to the advancement of endocrinology. This is demonstrated by our innovations in endocrine care: Pfizer UK was the first company to launch single-dose and multi-dose growth hormone (GH) delivery devices; it has built up the largest international databases of patients receiving GH therapy; and it produces the first and only GH receptor antagonist for the treatment of acromegaly.
BSPED has agreed a new 2-year partnership with Pfizer. The agreement is first of its kind for the Society, and aims to deliver maximum benefit to both organisations and the broader aim of advancing endocrinology.
To find out more about what Pfizer are doing to support the NHS and patients in the UK, please contact James Steed on firstname.lastname@example.org or Tel: +44 (0)7990530004.